| Sebelius Defends Medicare Nominee Health secretary Kathleen Sebelius rejected criticism of the Obama administration's nominee to run Medicare and Medicaid, saying Republicans were being unfair to Donald Berwick and she was confident he would be confirmed. online.wsj.com |
Bristol-Myers Squibb: Attractive, With a Couple Hiccups Jason Chew submits: With a 5% dividend, Bristol-Myers Squibb (BMY) provides one the highest yields you can find. This makes BMY a very attractive stock for income investors, especially considering today’s near-zero interest rate environment.There are however, a couple hiccups for investors to be aware of. Bristol is set to lose patent protection on its best-selling drugs, Plavix in 2011, and Avapro in 2012. Plavix and Avapro had sales of $6.1 and $1.3 billion, respectively in 2009, together accounting for about 39% of all revenue. Some of this revenue will be made up by growth from its portfolio of approved drugs. Abilify, already a $2.6 billion drug, increased sales 20% in 2009, the virology franchise of Baraclude, Reyataz, and Sustiva total another $3.4 billion in sales and grew about 10% in the period. Orencia and Sprycel are also doing well, albeit from smaller bases. Both products have the potential to reach over $1 billion in sales. Recently launched Onglyza, however, is off to a rather slow start. I estimate growth from these products can make up for approximately 40% of the revenue lost by Plavix and Avapro by 2013.Complete Story » seekingalpha.com |
Eli Lilly Approaches One of Biotech's Steepest Patent Cliffs The Burrill Report submits: By Michael FitzhughDespite a consensus-beating earnings report in July, investor pressure for stronger financial results has been unrelenting as Eli Lilly (LLY) approaches one of the steepest patent cliffs in the industry. An FDA advisory committee lent the company a ray of hope Thursday. It voted 8 to 6 in favor of recommending its blockbuster antidepressant, Cymbalta, be approved for the treatment of some types of chronic pain. But a string of disappointments preceding that result has turned up the heat. Complete Story » seekingalpha.com |
Almirall and Ironwood Announce Positive Results from a Phase 3 Trial with Linaclotide in Patients with Irritable Bowel Syndrome with Constipation [Business Wire] - BARCELONA & CAMBRIDGE, Mass.----Almirall, S.A. and Ironwood Pharmaceuticals, Inc. today announced positive top-line results from a Phase 3 clinical trial assessing the efficacy and safety of a once-daily dosing of linaclotide 266 mcg in patients with irritable bowel syndrome with constipation. us.rd.yahoo.com |
Hollywood Stars Talk About Epilepsy - Video Hollywood Movie Premiere Highlights National Epilepsy Awareness Month feedproxy.google.com |